Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib

Table 1 Patient demographics and laboratory findings

Characteristic
No. of patients, n	82
Age, mean ± SD, yr	63.5 ± 10.7
Male, n (%)	49 (60)
Laboratory findings
WBC count, mean ± SD	6259 ± 2667
Platelet count, mean ± SD, × 1000	225 ± 94
Neutrophil count, mean ± SD	4175 ± 2139
Lymphocyte count, mean ± SD	1462 ± 729
CRP, mean ± SD, mg/dL	12.5 ± 23.8
Albumin, mean ± SD, g/dL	3.5 ± 0.6
CA19-9, median, IU/mL	503.8
CEA, median, ng/mL	2.8
ECOG performance status score, n (%)
0	22 (27)
1	48 (58)
2	12 (15)
Inflammatory markers
NLR, median, range	3.1 (1-48)
PLR, median, range	141 (44-921)
CRP/albumin ratio, median, range	0.5 (0-37.7)
Staging
Locally advanced, n (%)	14 (17)
Metastatic, n (%)	68 (83)

WBC: White blood cell; CRP: C-reactive protein; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet to lymphocyte ratio; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; ECOG: Eastern Cooperative Oncology Group.